Panitumumab

Panitumumab is a recombinanthumanised monoclonal antibody used to treat epidermal growth factor receptor (EGFR)expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-,oxaliplatin-, and irinotecan containing chemotherapy regimens.

Indications

Metastatic Colorectal Cancer, It is indicated for the treatment of patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic cancer. Panitumumab is not indicated for the treatment of patients with RAS-mutant mCRC or for whom RAS mutation status is unknown.

Dosage

IV; Injection 100 mg/5 mL (20 mg/mL) and 400 mg/20 ml(20 mg/ml) in single-dose vial. The recommended dose of Panitumumab is 6 mg/kg, administered as an intravenous infusion over 60 minutes, every 14 days. If the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes. Administer doses higher than 1000 mg over 90 minutes. For intravenous infusion only. Do not administer Panitumumab as an intravenous push or bolus.

Contra-Indications

Panitumumab is contraindicated in patients with a history of severe infusion reactions, known hypersensitivity to the drug, or those with a history of interstitial lung disease.

Special Precautions

Paediatric: Safety and efficacy in pediatric patients have not been established. Pregnancy: Data not sufficient. Lactation: Because of the potential for serious adverse reactions in breastfed infants from Panitumumab, advise women not to breastfeed during treatment with Panitumumab and for 2 months after the final dose. Elderly: No overall differences in safety or efficacy were observed in elderly patients (? 65 years of age) treated with Panitumumab monotherapy.

Side Effects

Acne, dry skin, rash, itching, swelling or irritation around your fingernails or toenails, loss of appetite, nausea, diarrhea, blisters or ulcers in your mouth, red or swelling gums, trouble swallowing, tired feeling, weakness, and low potassium, intestinal obstruction, health deterioration

Drug Interactions

Caution is advised when combining panitumumab with other medications, especially those that may also affect the skin or the immune system. Consultation with a healthcare provider is essential to assess potential drug interactions.